¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå : »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, ½Å°æÀå¾Ö À¯Çüº°, ¾àÁ¦ Ŭ·¡½ºº°, À¯Åë ä³Îº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Diabetic Neuropathic Pain Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Neuropathy Type, Drug Class, By Distribution Channel By Region & Competition, 2020-2030F
»óǰÄÚµå : 1698041
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 185 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 16¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇß°í, ¿¹Ãø ±â°£ µ¿¾È 5.68%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀº ±¤¹üÀ§ÇÑ ÇコÄÉ¾î »ê¾÷¿¡¼­ ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ß·Î, Àü ¼¼°è ´ç´¢º´ À¯º´·ü Áõ°¡°¡ Ư¡ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â ±¹Á¦´ç´¢º´¿¬¸ÍÀº 20¼¼¿¡¼­ 79¼¼ »çÀÌÀÇ ¼ºÀÎ Áß ¾à 5¾ï 3,700¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è Àα¸ 10¸í Áß 1¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î º¸°íÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀº ´ç´¢º´ ȯÀÚÀÇ »ó´ç¼ö°¡ ¾Î°í ÀÖ´Â ´ç´¢º´ÀÇ °íÅ뽺·´°í ¼è¾àÇÏ°Ô ¸¸µå´Â ÇÕº´ÁõÀÔ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ´ç´¢º´¼º ½Å°æº´Áõ ȯÀÚ°¡ °Þ´Â ¸¸¼ºÀûÀÎ ÅëÁõ°ú ºÒÆíÇÔÀ» ¿ÏÈ­Çϱâ À§ÇÑ ´Ù¾çÇÑ ÀǾàǰ, ÀÇ·á±â±â, Ä¡·á ÁßÀç µîÀÌ Æ÷ÇԵ˴ϴÙ. ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ½ÅÈï±¹À» Áß½ÉÀ¸·Î ÇÑ ´ç´¢º´ À¯º´·ü Áõ°¡, ¼¼°è Àα¸ÀÇ °í·ÉÈ­ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ´ç´¢º´ÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ½Å°æº´Áõ¼º ÅëÁõÀ¸·Î À̾îÁö´Â ´ç´¢º´¼º ½Å°æº´ÁõÀÇ À¯º´·üµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó È¿°úÀûÀÎ ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÃÀåÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, CDC¿¡ µû¸£¸é ¹Ì±¹ Àα¸ÀÇ 10.5%¿¡ ÇØ´çÇÏ´Â ¾à 3,420¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â Áø´ÜµÈ °æ¿ì¿Í Áø´ÜµÇÁö ¾ÊÀº °æ¿ì¸¦ ¸ðµÎ Æ÷ÇÔÇÕ´Ï´Ù. ´ç´¢º´ Áø´ÜÀ» ¹ÞÁö ¾Ê¾Ò°Å³ª ¿¹ºñ ´ç´¢º´ ȯÀÚµµ »ó´ç¼ö¿¡ ´ÞÇϰí, ´ç´¢º´ °ü¸®¿Í ¿¹¹æ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 16¾ï 4,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 22¾ï 7,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 5.68%
±Þ¼ºÀå ºÎ¹® ¸»ÃʽŰæÀå¾Ö
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

´ç´¢º´ À¯Çà È®´ë

ÁÖ¿ä ½ÃÀå À̽´

Ä¡·á ÀúÇ×¼º

ÁÖ¿ä ½ÃÀå µ¿Çâ

ȯÀÚ Áß½ÉÀÇ ÀÇ·á

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦6Àå À¯·´ÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦7Àå ºÏ¹ÌÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦8Àå ³²¹ÌÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦9Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå Àü¸Á

Á¦10Àå ½ÃÀå ¿ªÇÐ

Á¦11Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦12Àå ¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå : SWOT ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå ¸®¼­Ä¡»ç¿¡ ´ëÇØ & ¸éÃ¥»çÇ×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.64 Billion
Market Size 2030USD 2.27 Billion
CAGR 2025-20305.68%
Fastest Growing SegmentPeripheral Neuropathy
Largest MarketNorth America

Key Market Drivers

Escalating Diabetes Epidemic

The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.

Key Market Challenges

Treatment Resistance

One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.

Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.

Key Market Trends

Patient-Centered Care

Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.

Key Market Players

Eli Lilly and Company

Grunenthal GmBH

Collegium Pharmaceutical, Inc.

Lupin Ltd

Daiichi Sankyo Inc.

Azurity Pharmaceuticals, Inc.

Novartis AG

Pfizer, Inc.

Endo International plc. (Par Pharmaceutical)

Johnson & Johnson

Report Scope:

In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Neuropathic Pain Market, By Neuropathy Type:

Diabetic Neuropathic Pain Market, By Drug Class:

Diabetic Neuropathic Pain Market, By Distribution Channel:

Diabetic Neuropathic Pain Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.

Available Customizations:

Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Diabetic Neuropathic Pain Market Outlook

5. Asia Pacific Diabetic Neuropathic Pain Market Outlook

6. Europe Diabetic Neuropathic Pain Market Outlook

7. North America Diabetic Neuropathic Pain Market Outlook

8. South America Diabetic Neuropathic Pain Market Outlook

9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook

10. Market Dynamics

11. Market Trends & Developments

12. Global Diabetic Neuropathic Pain Market: SWOT Analysis

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â